Human therapeutic monoclonal antibodies and other targeted biological therapies

Vaccinex, Inc. is at the forefront of developing innovative therapies for cancer and neurodegenerative diseases, primarily through its lead drug candidate, pepinemab. This first-in-class anti-semaphorin 4D (SEMA4D) antibody is designed to inhibit the activity of SEMA4D, a molecule implicated in immune evasion by tumors and neuroinflammation in chronic neurological disorders. By blocking SEMA4D, pepinemab aims to enhance immune responses against tumors and mitigate the inflammatory processes that contribute to diseases such as Alzheimer's and Huntington's disease. The company is actively conducting clinical trials to evaluate the efficacy of pepinemab in these conditions, with promising results indicating potential cognitive benefits and reduced neuroinflammation.

In addition to pepinemab, Vaccinex leverages its proprietary ActivMAb® technology platform for antibody discovery and development. This platform enables the efficient generation of high-affinity human monoclonal antibodies, particularly against challenging targets like multi-pass membrane proteins. The technology facilitates the rapid selection of antibody candidates that have undergone quality control in mammalian cells, ensuring their suitability for therapeutic development. Vaccinex is also exploring other therapeutic candidates, such as VX5/5261, an antibody targeting CXCL13 for autoimmune disorders, further expanding its pipeline and commitment to addressing complex diseases through innovative approaches.

United States

Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.

Cancer

Central Nervous System (CNS)

Immune System Diseases

Inflammatory disorders

Vaccinex 

Huntington's disease

<p class="font_7">Pepinemab is a novel monoclonal antibody that blocks the activity of SEMA4D, and preclinical testing has demonstrated the beneficial effects of anti-SEMA4D treatment in a variety of neurodegenerative disease models. Vaccinex is committed to the development of this potentially important antibody that has the potential to help people with different neurodegenerative disorders that share common mechanisms of pathology.</p>

Vaccinex

Company Details